Max
07-24-2002, 11:11 AM
CytRx Corporation Appoints Nobel Laureate, Dr. Louis Ignarro, to Board of Directors
7/24/2002 8:31:00 AM
LOS ANGELES, Jul 24, 2002 /PRNewswire-FirstCall via COMTEX/ -- CytRx Corporation (CYTR) today announced the election of Louis Ignarro, Ph.D. to its Board of Directors.
CBS MARKETWATCH TOP NEWS
Dow keeps triple-digit gains
Lawmakers reach corporate reform pact
Rigas, ex-Adelphia chief, arrested
Citigroup, Morgan: From dogs to darlings
Sign up for FREE e-newsletters
TRACK THESE TOPICS
My Portfolio Alerts
Company: CytRx Corporation Add
Create
Create A Portfolio | Create An Alert
Steven A. Kriegsman, Chief Executive Officer, commented, "The CytRx team and I are elated to have the opportunity to work with Dr. Ignarro. He will bring to CytRx the experience of a luminous career in medicine that we will be extremely fortunate to benefit from."
Dr. Ignarro added that, "I am most enthused about working with Steve and the CytRx team and look forward to helping to bring CytRx to the next level. This will be a great learning experience for me."
Louis Ignarro, Ph.D., Nobel Laureate in Medicine, serves as the Jerome J. Bezler, M.D. Distinguished Professor of Pharmacology in the Department of Molecular and Medical Pharmacology at the UCLA School of Medicine. He has been at the UCLA School of Medicine since 1985 as a Professor, Acting Chairman and Assistant Dean.
Dr. Ignarro has received countless awards for his work in medicine and as a professor, including the Nobel Prize for Medicine or Physiology in 1998. He is also an active participant in numerous science/medical associations including the American Academy of Arts and Sciences, National Academy of Sciences, American Society of Hematology, American Society for Pharmacology and Experimental Therapeutics. He is founder and editor-in-chief of "Nitric Oxide" Biology and Chemistry (Academic Press).
Among his special awards are the Roussel Uclaf Prize for Cell Communication and Signaling, the CIBA Award for Hypertension Research, the Honoris Causa Doctorate Degree from the University of Buenos Aires, Republic of Argentina and the Basic Research Prize of the American Heart Association. Dr. Ignarro is a member of the Scientific Advisory Boards of the French pharmaceutical company, NicOx, S.A. He received a B.S. in Pharmacy from Columbia University in New York and his Ph.D. in Pharmacology from the University of Minnesota.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical company focused on the development and commercialization of high-value human therapeutics. The company's current research and development activities include CRL-5861, an intravenous agent for treatment of sickle cell disease and other acute vaso-occlusive disorders, and TranzFect, a delivery technology for DNA-based vaccines. CytRx has licensed TranzFect to Merck & Co., Inc. for use in Merck's efforts to development DNA-based vaccines for HIV and three other infectious diseases. All other uses of TranzFect for enhancement of viral or non-viral delivery of polynucleotides (such as DNA and RNA) have been licensed to Vical, Incorporated. CytRx has a research pipeline in the areas of muscular dystrophy, cancer, spinal cord injury, vaccine delivery, gene therapy and food animal feed additives.
CytRx's wholly owned subsidiary, GGC Pharmaceuticals, Inc., is a genomics holding company that currently has a forty percent ownership interest in Blizzard Genomics, Inc in Minneapolis, Minnesota and a five percent ownership interest in Psynomics, Inc., a central nervous system genomics company in San Diego, CA. Blizzard Genomics, Inc. is developing instrumentation, software, and consumable supplies (including patent-pending "T-Chip" and "Contact" technologies) for the genomics industry. GGC expects that DNA chips will significantly impact a broad range of biomedical and agricultural businesses. These include drug development, diagnostic testing, forensics, environmental testing and plant biotechnology. Psynomics, Inc. is a genomics company developing technology for the diagnosis and treatment of neuropsychiatric diseases and has rights to access a significant database of patient data and corresponding tissue samples.
CAUTIONARY NOTICE ABOUT FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to integration of CytRx and GGC, available financing for continued operations and the company's inability to successfully develop and market its technology. Additional uncertainties and risks are described in the CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X60160726
SOURCE CytRx Corporation
CONTACT: Steven A. Kriegsman, Chief Executive Officer of CytRx Corporation, +1-310-826-5648, steven@kriegsmangroup.com; or Loren Brown of Madison & Wall Worldwide, +1-407-682-2001, Loren@insidewallstreet.com, for CytRx CorporationURL: http://www.cytrx.comhttp://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
7/24/2002 8:31:00 AM
LOS ANGELES, Jul 24, 2002 /PRNewswire-FirstCall via COMTEX/ -- CytRx Corporation (CYTR) today announced the election of Louis Ignarro, Ph.D. to its Board of Directors.
CBS MARKETWATCH TOP NEWS
Dow keeps triple-digit gains
Lawmakers reach corporate reform pact
Rigas, ex-Adelphia chief, arrested
Citigroup, Morgan: From dogs to darlings
Sign up for FREE e-newsletters
TRACK THESE TOPICS
My Portfolio Alerts
Company: CytRx Corporation Add
Create
Create A Portfolio | Create An Alert
Steven A. Kriegsman, Chief Executive Officer, commented, "The CytRx team and I are elated to have the opportunity to work with Dr. Ignarro. He will bring to CytRx the experience of a luminous career in medicine that we will be extremely fortunate to benefit from."
Dr. Ignarro added that, "I am most enthused about working with Steve and the CytRx team and look forward to helping to bring CytRx to the next level. This will be a great learning experience for me."
Louis Ignarro, Ph.D., Nobel Laureate in Medicine, serves as the Jerome J. Bezler, M.D. Distinguished Professor of Pharmacology in the Department of Molecular and Medical Pharmacology at the UCLA School of Medicine. He has been at the UCLA School of Medicine since 1985 as a Professor, Acting Chairman and Assistant Dean.
Dr. Ignarro has received countless awards for his work in medicine and as a professor, including the Nobel Prize for Medicine or Physiology in 1998. He is also an active participant in numerous science/medical associations including the American Academy of Arts and Sciences, National Academy of Sciences, American Society of Hematology, American Society for Pharmacology and Experimental Therapeutics. He is founder and editor-in-chief of "Nitric Oxide" Biology and Chemistry (Academic Press).
Among his special awards are the Roussel Uclaf Prize for Cell Communication and Signaling, the CIBA Award for Hypertension Research, the Honoris Causa Doctorate Degree from the University of Buenos Aires, Republic of Argentina and the Basic Research Prize of the American Heart Association. Dr. Ignarro is a member of the Scientific Advisory Boards of the French pharmaceutical company, NicOx, S.A. He received a B.S. in Pharmacy from Columbia University in New York and his Ph.D. in Pharmacology from the University of Minnesota.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical company focused on the development and commercialization of high-value human therapeutics. The company's current research and development activities include CRL-5861, an intravenous agent for treatment of sickle cell disease and other acute vaso-occlusive disorders, and TranzFect, a delivery technology for DNA-based vaccines. CytRx has licensed TranzFect to Merck & Co., Inc. for use in Merck's efforts to development DNA-based vaccines for HIV and three other infectious diseases. All other uses of TranzFect for enhancement of viral or non-viral delivery of polynucleotides (such as DNA and RNA) have been licensed to Vical, Incorporated. CytRx has a research pipeline in the areas of muscular dystrophy, cancer, spinal cord injury, vaccine delivery, gene therapy and food animal feed additives.
CytRx's wholly owned subsidiary, GGC Pharmaceuticals, Inc., is a genomics holding company that currently has a forty percent ownership interest in Blizzard Genomics, Inc in Minneapolis, Minnesota and a five percent ownership interest in Psynomics, Inc., a central nervous system genomics company in San Diego, CA. Blizzard Genomics, Inc. is developing instrumentation, software, and consumable supplies (including patent-pending "T-Chip" and "Contact" technologies) for the genomics industry. GGC expects that DNA chips will significantly impact a broad range of biomedical and agricultural businesses. These include drug development, diagnostic testing, forensics, environmental testing and plant biotechnology. Psynomics, Inc. is a genomics company developing technology for the diagnosis and treatment of neuropsychiatric diseases and has rights to access a significant database of patient data and corresponding tissue samples.
CAUTIONARY NOTICE ABOUT FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to integration of CytRx and GGC, available financing for continued operations and the company's inability to successfully develop and market its technology. Additional uncertainties and risks are described in the CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X60160726
SOURCE CytRx Corporation
CONTACT: Steven A. Kriegsman, Chief Executive Officer of CytRx Corporation, +1-310-826-5648, steven@kriegsmangroup.com; or Loren Brown of Madison & Wall Worldwide, +1-407-682-2001, Loren@insidewallstreet.com, for CytRx CorporationURL: http://www.cytrx.comhttp://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.